1. Chen D, Yang Z, Chen X, et al., The effect of Lactobacillus rhamnosus hsryfm 1301 on the intestinal microbiota of a hyperlipidemic rat model. BMC Complement Altern Med 2014. 14: 386.
2. Lahti L, Salonen A, Kekkonen RA, et al. Associations between the human intestinal microbiota, Lactobacillus rhamnosus GG and serum lipids indicated by integrated analysis of high-throughput profiling data. Peer J 2013; 1: e32.
3. London LE, Kumar AH, Wall R, et al. Exopolysaccharide-producing probiotic Lactobacilli reduce serum cholesterol and modify enteric microbiota in ApoEdeficient mice. J Nutr 2014; 144(12): 1956-62.
4. Su B, Liu H, Li J, et al. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J Diabetes 2014. http://onlinelibrary.wiley.com/doi/10.1111/1753- 0407.12232/full
5. Kiessling, G, Schneider J, Jahreis G Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur J Clin Nutr 2002. 56(9): 843-9.
6. Rajkumar H, Mahmood N, Kumar M, et al. Effect of probiotic (VSL#3) and omega- 3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial. Mediators Inflamm 2014; 2014: http://www.hindawi.com/journals/mi/2014/348959/ref/.
7. Hatakka K, Mutanen M, Holma R, et al. Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp shermanii JS administered in capsules is ineffective in lowering serum lipids. J Am Coll Nutr 2008; 27(4): 441-7.
8. Lewis SJ, Burmeister S. A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids. Eur J Clin Nutr 2005; 59(6): 776-80.
9. Kumar R, Rajkumar H, Kumar M, et al. Molecular cloning, characterization and heterologous expression of bile salt hydrolase (Bsh) from Lactobacillus fermentum NCDO394. Mol Biol Rep 2013; 40(8): 5057-66.
10. Kumar M, Nagpal R, Kumar R, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012; 2012: http://www. hindawi.com/journals/jdr/2012/902917/.
11. Kumar M, Rakesh S, Nagpal R, et al. Probiotic Lactobacillus rhamnosus GG and Aloe vera gel improve lipid profiles in hypercholesterolemic rats. Nutrition 2013; 29(3): 574-9.
12. Tsun JG, Shiu SW, Wong Y, et al. Impact of serum amyloid A on cellular cholesterol efflux to serum in type 2 diabetes mellitus. Atherosclerosis 2013; 231(2): 405-10.
13. Sarkisova IA, Rameev VV, Kozlovskaya LV. Rheumatoid arthritis as the main etiological factor of amyloidosis. Klinicheskaia gerontologiia 2009; 15 (2): 14-20. Russian (Саркисова И.А., Рамеев В.В., Козловская Л.В. Ревматоидный артрит как основная причина развития АА-амилоидоза. Клиническая геронтология 2009; 15 (2): 14-20).
14. Reigstad CS, Lunden GO, Felin J, et al. Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLoS One 2009; 4(6): e5842.
15. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490(7418): 55-60.
16. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498(7452): 99-103.
17. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444(7122): 1022-3.
18. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444(7122): 1027-31.
19. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5(2): e9085.
20. Fitzgerald KA, Rowe DC, Golenbock DT. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect 2004; 6(15): 1361-7.
21. Tarini J, Wolever TM. The fermentable fibre inulin increases postprandial serum shortchain fatty acids and reduces free-fatty acids and ghrelin in healthy subjects. Appl Physiol Nutr Metab 2010; 35(1): 9-16.
22. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012; 61(2): 364-71.
23. De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014; 156(1-2): 84-96.
24. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10(3): 167-77.
25. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50(11): 2374-83.
26. Muccioli GG, Naslain D, Backhed F, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 2010; 6: 392.
27. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 2013; 110(22): 9066-71.
28. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3(9): 771-84.
29. Muccioli GG. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 2010; 15(11-12): 474-83.
30. Geurts L, Lazarevic V, Derrien M, et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol 2011; 2: 149.
